SciFluor Life Sciences, LLC, a drug development technology company that provides a revolutionary capability to enable late-stage fluorination of pharmaceutical drug candidates, announced that it has appointed Arthur Hiller, recent CEO of venture-backed cardiovascular device start-up Heartscape Technologies, Inc., and former Senior Vice President at Millennium Pharmaceuticals, as its Chief Executive Officer. The company utilizes patented technology developed by Tobias Ritter, PhD., Associate Professor of Chemistry and Chemical Biology at Harvard University, to provide drug companies with a new tool in their arsenal to increase the likelihood of bringing new drug candidates to market.
